SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 124 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $301,290 | -30.7% | 20,750 | -0.0% | 0.01% | -31.2% |
Q2 2023 | $434,507 | -11.5% | 20,760 | -10.7% | 0.02% | 0.0% |
Q1 2023 | $491,040 | -25.6% | 23,250 | -10.4% | 0.02% | -33.3% |
Q4 2022 | $660,173 | +7.2% | 25,940 | +1.2% | 0.02% | +4.3% |
Q3 2022 | $616,000 | +34.2% | 25,640 | +7.6% | 0.02% | +43.8% |
Q2 2022 | $459,000 | +7.5% | 23,840 | -3.1% | 0.02% | +23.1% |
Q1 2022 | $427,000 | -20.6% | 24,590 | 0.0% | 0.01% | -13.3% |
Q4 2021 | $538,000 | +13.5% | 24,590 | -0.8% | 0.02% | +7.1% |
Q3 2021 | $474,000 | +9.5% | 24,790 | -1.8% | 0.01% | +7.7% |
Q2 2021 | $433,000 | -23.9% | 25,240 | -0.8% | 0.01% | -27.8% |
Q1 2021 | $569,000 | +0.2% | 25,440 | -0.3% | 0.02% | -5.3% |
Q4 2020 | $568,000 | +47.2% | 25,525 | -2.3% | 0.02% | +26.7% |
Q3 2020 | $386,000 | 0.0% | 26,125 | +0.4% | 0.02% | -11.8% |
Q2 2020 | $386,000 | +238.6% | 26,025 | +111.9% | 0.02% | +183.3% |
Q2 2019 | $114,000 | – | 12,280 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |